A prospective ramdomized control trial of comparing PPI vesus P-CAB in the treatment of hemorrhagic peptic ulcer disease
Phase 3
- Conditions
- hemorrhagic peptic ulcer
- Registration Number
- JPRN-UMIN000021992
- Lead Sponsor
- Aichi medical university Department of Gastroentelorogy
- Brief Summary
canceled
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
The patients of hemorrhagic peptic ulcer are hard to do endoscopic hemostasis. The patients can not take medicine. The patients who do not agree with this study. Tha patients who take atazanavir sulfate or rirupibirin hydrochloride.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The reduction rate of ulcer for a week
- Secondary Outcome Measures
Name Time Method The rate of re-bleeding, the day of hospitalization, the rate of blood transfusion, The transfer rate of surgery or IVR, The influence of anti-platelet/anti-coaglant,The cure rate for 28 days, The cure rate for 56 days